On January 9, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's self-developed bispecific antibody drug (Project No.: IMM0306) targeting both CD47 and CD20 has obtained the US FDA clinical trial research license. It was only 30 days before the application for IND was submitted to FDA that the company obtained the clinical trial research license, which indicated that the company team had made excellent preparation for CMC and clinical research protocol, and laid a good foundation for many projects to apply for IND in the United States in the future.